2 Information about secukinumab

Marketing authorisation indication

2.1 Secukinumab (Cosentyx, Novartis) is 'indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) in adults who have responded inadequately to non-steroidal anti-inflammatory drugs (NSAIDs)'.

Dosage in the marketing authorisation

2.2 The dosage schedule is in the summary of product characteristics.


2.3 The list price is £1,218.78 for 2 pre-filled pens or syringes containing 150 mg per 1 ml solution (excluding VAT, BNF online accessed March 2021). Annual cost of treatment for the first year is £9,750.24 and subsequent years is £7,312.68. The company has a commercial arrangement. This makes secukinumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)